ArticleAntimicrobial agents and chemotherapy2010
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 78 citations in OpenAlex.
- Strain sharing and mobile genetic elements shape the interconnected resistomes of Campylobacter coli in Brazil.BMC biology · 2025Article
- Consortium ofAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Development of Meropenem Resistance in a Multidrug-Resistant Campylobacter coli Strain Causing Recurrent Bacteremia in a Hematological Malignancy Patient.Antimicrobial agents and chemotherapy · 2023Article
- Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Prevalence, species diversity, and antimicrobial susceptibility ofIranian journal of microbiology · 2022Article
- Antimicrobial Resistance in Campylobacter coli and Campylobacter jejuni from Human Campylobacteriosis in Taiwan, 2016 to 2019.Antimicrobial agents and chemotherapy · 2022Article
- Antimicrobial susceptibility testing and successful treatment of hospitalised patients with extensively drug-resistant Campylobacter jejuni infections linked to a pet store puppy outbreak.Journal of global antimicrobial resistance · 2021Article
- Significant contribution of the CmeABC Efflux pump in high-level resistance to ciprofloxacin and tetracycline in Campylobacter jejuni and Campylobacter coli clinical isolates.Annals of clinical microbiology and antimicrobials · 2021Article
- Longitudinal Study of the Distribution of Antimicrobial-ResistantAnimals : an open access journal from MDPI · 2021Article
- New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Antimicrobial Resistance ofFoodborne pathogens and disease · 2020Article
- Reuterin Demonstrates Potent Antimicrobial Activity Against a Broad Panel of Human and Poultry MeatMicroorganisms · 2020Article
- Characterization and Phylogenetic Analysis ofInternational journal of environmental research and public health · 2019Article
- Technical specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria from food-producing animals and food.EFSA journal. European Food Safety Authority · 2019Article
- Overlap of Antibiotic ResistantFrontiers in microbiology · 2019Article
- Stress Response and Virulence Potential Modulating Effect of Peppermint Essential Oil inBioMed research international · 2019Article
- A Historical Review on Antibiotic Resistance of FoodborneFrontiers in microbiology · 2019Review
- Emergence of Carbapenem Non-susceptible Campylobacter coli after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia.Internal medicine (Tokyo, Japan) · 2018Article
- In vitro activity of fosfomycin against Campylobacter isolates from poultry and wild birds.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a paucity of information regarding antimicrobial agents that are suitable to treat severe infections caused by multidrug-resistant Campylobacter spp. Our aim was to identify agents that are potentially effective against multiresistant Campylobacter strains. The in vitro activities of 20 antimicrobial agents against 238 Campylobacter strains were analyzed by determining MICs by the agar plate dilution method or the Etest. These strains were selected from 1,808 Campylobacter isolates collected from Finnish patients between 2003 and 2005 and screened for macrolide susceptibility by using the disk diffusion test. The 238 strains consisted of 183 strains with erythromycin inhibition zone diameters of < or =23 mm and 55 strains with inhibition zone diameters of >23 mm. Of the 238 Campylobacter strains, 19 were resistant to erythromycin by MIC determinations (MIC > or = 16 microg/ml). Given that the resistant strains were identified among the collection of 1,808 isolates, the frequency of erythromycin resistance was 1.1%. All erythromycin-resistant strains were multidrug resistant, with 18 (94.7%) of them being resistant to ciprofloxacin (MIC > or = 4 microg/ml). The percentages of resistance to tetracycline and amoxicillin-clavulanic acid (co-amoxiclav) were 73.7% and 31.6%, respectively. All macrolide-resistant strains were susceptible to imipenem, meropenem, and tigecycline. Ten (52.6%) multiresistant strains were identified as being Campylobacter jejuni strains, and 9 (47.4%) were identified as being C. coli strains. These data demonstrate that the incidence of macrolide resistance was low but that the macrolide-resistant Campylobacter strains were uniformly multidrug resistant. In addition to the carbapenems, tigecycline was also highly effective against these multidrug-resistant Campylobacter strains in vitro. Its efficacy for the treatment of human campylobacteriosis should be evaluated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.